Robert W. Baird Lowers Inspire Medical Systems (NYSE:INSP) Price Target to $248.00

Inspire Medical Systems (NYSE:INSP) had its target price lowered by Robert W. Baird from $252.00 to $248.00 in a report released on Tuesday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Robert W. Baird’s price target would suggest a potential upside of 32.50% from the stock’s previous close.

Several other analysts have also recently weighed in on the stock. Stifel Nicolaus decreased their price objective on shares of Inspire Medical Systems from $200.00 to $190.00 and set a “hold” rating on the stock in a research note on Tuesday, January 21st. Bank of America upgraded Inspire Medical Systems from a “neutral” rating to a “buy” rating and increased their price target for the stock from $220.00 to $255.00 in a research report on Wednesday, November 20th. Royal Bank of Canada reiterated an “outperform” rating and issued a $260.00 price objective on shares of Inspire Medical Systems in a research report on Tuesday, November 5th. KeyCorp reissued an “overweight” rating and issued a $234.00 price objective (down previously from $236.00) on shares of Inspire Medical Systems in a research note on Friday, January 24th. Finally, Morgan Stanley lowered their target price on Inspire Medical Systems from $230.00 to $220.00 and set an “overweight” rating for the company in a research note on Tuesday. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $228.82.

Inspire Medical Systems Stock Up 1.7 %

Shares of INSP opened at $187.17 on Tuesday. The company has a 50-day moving average price of $189.39 and a two-hundred day moving average price of $191.39. The stock has a market cap of $5.61 billion, a price-to-earnings ratio of 174.93 and a beta of 1.32. Inspire Medical Systems has a 12 month low of $123.00 and a 12 month high of $257.40.

Inspire Medical Systems (NYSE:INSP) last posted its earnings results on Monday, February 10th. The company reported $1.15 EPS for the quarter, topping the consensus estimate of $0.74 by $0.41. Inspire Medical Systems had a return on equity of 5.30% and a net margin of 4.37%. Equities research analysts expect that Inspire Medical Systems will post 1.33 EPS for the current fiscal year.

Institutional Trading of Inspire Medical Systems

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. First Horizon Advisors Inc. boosted its stake in shares of Inspire Medical Systems by 885.7% in the 4th quarter. First Horizon Advisors Inc. now owns 138 shares of the company’s stock valued at $26,000 after purchasing an additional 124 shares during the last quarter. True Wealth Design LLC acquired a new position in Inspire Medical Systems in the third quarter valued at approximately $30,000. Farther Finance Advisors LLC boosted its stake in Inspire Medical Systems by 1,158.3% in the third quarter. Farther Finance Advisors LLC now owns 151 shares of the company’s stock valued at $32,000 after acquiring an additional 139 shares during the last quarter. Huntington National Bank grew its holdings in Inspire Medical Systems by 228.3% during the 4th quarter. Huntington National Bank now owns 174 shares of the company’s stock worth $32,000 after acquiring an additional 121 shares during the period. Finally, Harbour Investments Inc. grew its holdings in Inspire Medical Systems by 101.0% during the 4th quarter. Harbour Investments Inc. now owns 197 shares of the company’s stock worth $37,000 after acquiring an additional 99 shares during the period. 94.91% of the stock is currently owned by institutional investors and hedge funds.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.